A Phase 2 interventional study of Saccharomyces boulardii in Diarrhea and HIV Infections, sponsored by Biocodex. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Biocodex · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 249 studies in Diarrhea with a site in United States — 15 open to participants now, 20 under way, none of them phase 3. Diarrhea · United States.
Among the 249 studies in Diarrhea with a site in United States, this one is the 83rd largest by enrollment of the 223 interventional ones that give a count, is one of 64 in phase 2, and was the 3rd registered.
879 studies on the registry are indexed under Diarrhea; 78 are open to participants now.
Browse Diarrhea studies →15 of the 249 studies in Diarrhea with a site in United States are open now. Recruiting first, the newest first:
Virginia Polytechnic Institute and State University · Sites in United States
Ages 6 mo+ · Healthy volunteers
Maryam Lustberg · Sites in United States
Ages 18+ · Healthy volunteers
Eli Lilly and Company · Sites in United States, Belgium, Canada and 7 more countries
Ages 18–75
Bausch Health Americas, Inc. · Sites in United States
Ages 6–12
Peach Perfect · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
249 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 80 · Phase 3 43 · Phase 4 24
First in 1996; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is below the median of 138 across 739 interventional studies indexed under Diarrhea.
Median enrollment 63 across the 223 interventional studies, 190 across the 16 observational. Of the 213 that completed or were terminated, 95 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 249 have an industry lead sponsor. The 10 most frequent:
Biocodex is the lead sponsor of 19 studies on the registry; 6 are open to participants now.
Biocodex has 1 study filed under Diarrhea — fewer than ten, so there is no comparison to draw.
10 of the studies in Diarrhea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01822470Indiana UniversitySmall Intestinal Bacterial Overgrowth: A Prospective Registry | 2026-12 |
| NCT05465629ViomeViome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions | 2026-12 |
| NCT06684470Mayo ClinicNovel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator | 2026-12-19 |
| NCT06801067Memorial Sloan Kettering Cancer CenterA Study of SER-155 to Treat Diarrhea in People on Immunotherapy | 2027-01-24 |
| NCT04826991Temple UniversityWells and Enteric Disease Transmission | 2027-03-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 249 studies in Diarrhea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the efficacy of Saccharomyces boulardii (a nonpathogenic yeast) in producing a significant reduction in diarrheal symptoms in HIV-infected patients with chronic diarrhea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Concurrent Medication:
Allowed:
Patients must have:
Patients who are on antiviral medications for HIV infection must have received such medication for at least 2 weeks and must remain on stable dose for weeks 1 and 2 of study.
Prior Medication:
Allowed:
Exclusion Criteria
Concurrent Medication:
Excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is completed, as verified in Mar 1996. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Saccharomyces cerevisiae
Biocodex